Petaluma biotech startup Oculus Innovative Sciences has launched a new infection-fighting product in the United States, Microcyn Skin and Wound Gel.
The product, approved as a medical device by the U.S. Food and Drug Administration, is available over the counter or by prescription.
Medicare and Medicaid have added it to the list of products they will pay for, creating a larger market for Oculus, according to company CEO Hoji Alimi. ?We plan to aggressively market it to the U.S. health care community,? he said.
Oculus also is moving to get regulatory approvals to distribute the product outside the U.S., Alimi said.
The prescription version is intended for treating leg ulcers, pressure ulcers, diabetic ulcers and debrided wounds.
Oculus? Microcyn-based products are sold in the U.S., Mexico, Europe, China and several Middle East countries. The company has 26 employees at its headquarters in Petaluma.